Mitochondrial DNA Haplogroups and Susceptibility to Neuroblastoma.
Age of Onset
Case-Control Studies
Cells, Cultured
Child
Cohort Studies
DNA, Mitochondrial
/ genetics
Datasets as Topic
/ statistics & numerical data
Gene Frequency
Genetic Association Studies
Genetic Predisposition to Disease
Haplotypes
Humans
Neuroblastoma
/ epidemiology
Polymorphism, Single Nucleotide
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
14 12 2020
14 12 2020
Historique:
received:
31
07
2019
revised:
24
01
2020
accepted:
19
02
2020
pubmed:
26
2
2020
medline:
29
4
2021
entrez:
26
2
2020
Statut:
ppublish
Résumé
Neuroblastoma is a childhood malignancy that arises from the developing sympathetic nervous system. Although mitochondrial dysfunctions have been implicated in the pathophysiology of neuroblastoma, the role of mitochondrial DNA (mtDNA) has not been extensively investigated. A total of 2404 Caucasian children diagnosed with neuroblastoma and 9310 ancestry-matched controls were recruited at the Children's Hospital of Philadelphia. The mtDNA haplogroups were identified from SNP array data of two independent cohorts. We conducted a case-control study to explore potential associations of mtDNA haplogroups with the susceptibility of neuroblastoma. The genetic effect of neuroblastoma was measured by odds ratios (ORs) of mitochondrial haplogroups. All tests were two-sided. Haplogroup K was statistically significantly associated with reduced risk of neuroblastoma in the discovery cohort consisting of 1474 cases and 5699 controls (OR = 0.72, 95% confidence interval [CI] = 0.57 to 0.90; P = 4.8 × 10-3). The association was replicated in an independent cohort (OR = 0.69, 95% CI = 0.53 to 0.92; P = .01) of 930 cases and 3611 controls. Pooled analysis was performed by combining the two data sets. The association remained highly statistically significant after correction for multiple testing (OR = 0.71, 95% CI = 0.59 to 0.84, P = 1.96 × 10-4, Pcorrected = .002). Further analysis focusing on neuroblastoma subtypes indicated haplogroup K was more associated with high-risk neuroblastoma (OR = 0.57, 95% CI = 0.43 to 0.76; P = 1.46 × 10-4) than low-risk and intermediate-risk neuroblastoma. Haplogroup K is an independent genetic factor associated with reduced risk of developing neuroblastoma in European descents. These findings provide new insights into the genetic basis of neuroblastoma, implicating mitochondrial DNA encoded proteins in the etiology of neuroblastoma.
Sections du résumé
BACKGROUND
Neuroblastoma is a childhood malignancy that arises from the developing sympathetic nervous system. Although mitochondrial dysfunctions have been implicated in the pathophysiology of neuroblastoma, the role of mitochondrial DNA (mtDNA) has not been extensively investigated.
METHODS
A total of 2404 Caucasian children diagnosed with neuroblastoma and 9310 ancestry-matched controls were recruited at the Children's Hospital of Philadelphia. The mtDNA haplogroups were identified from SNP array data of two independent cohorts. We conducted a case-control study to explore potential associations of mtDNA haplogroups with the susceptibility of neuroblastoma. The genetic effect of neuroblastoma was measured by odds ratios (ORs) of mitochondrial haplogroups. All tests were two-sided.
RESULTS
Haplogroup K was statistically significantly associated with reduced risk of neuroblastoma in the discovery cohort consisting of 1474 cases and 5699 controls (OR = 0.72, 95% confidence interval [CI] = 0.57 to 0.90; P = 4.8 × 10-3). The association was replicated in an independent cohort (OR = 0.69, 95% CI = 0.53 to 0.92; P = .01) of 930 cases and 3611 controls. Pooled analysis was performed by combining the two data sets. The association remained highly statistically significant after correction for multiple testing (OR = 0.71, 95% CI = 0.59 to 0.84, P = 1.96 × 10-4, Pcorrected = .002). Further analysis focusing on neuroblastoma subtypes indicated haplogroup K was more associated with high-risk neuroblastoma (OR = 0.57, 95% CI = 0.43 to 0.76; P = 1.46 × 10-4) than low-risk and intermediate-risk neuroblastoma.
CONCLUSIONS
Haplogroup K is an independent genetic factor associated with reduced risk of developing neuroblastoma in European descents. These findings provide new insights into the genetic basis of neuroblastoma, implicating mitochondrial DNA encoded proteins in the etiology of neuroblastoma.
Identifiants
pubmed: 32096864
pii: 5756215
doi: 10.1093/jnci/djaa024
pmc: PMC7735767
doi:
Substances chimiques
DNA, Mitochondrial
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1259-1266Subventions
Organisme : NCI NIH HHS
ID : R01 CA204974
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA220500
Pays : United States
Organisme : NHGRI NIH HHS
ID : U01 HG006830
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA124709
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA180692
Pays : United States
Informations de copyright
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.
Références
Biomed Res Int. 2018 Feb 25;2018:1812535
pubmed: 29682521
Immune Netw. 2017 Apr;17(2):77-88
pubmed: 28458619
Nat Genet. 2015 Aug;47(8):864-71
pubmed: 26121087
PLoS Genet. 2017 May 18;13(5):e1006787
pubmed: 28545128
Nat Genet. 2006 Aug;38(8):904-9
pubmed: 16862161
Curr Opin Genet Dev. 2017 Feb;42:81-90
pubmed: 28458126
Transl Pediatr. 2015 Jan;4(1):20-32
pubmed: 26835356
Nat Genet. 2012 Oct;44(10):1126-30
pubmed: 22941191
Front Plant Sci. 2018 Sep 04;9:1272
pubmed: 30233617
Methods Mol Biol. 2009;471:291-303
pubmed: 19109786
Nat Rev Immunol. 2017 Oct;17(10):608-620
pubmed: 28669986
Lancet Neurol. 2010 May;9(5):498-503
pubmed: 20362514
Clin Cancer Res. 2018 Jun 1;24(11):2482-2490
pubmed: 29420223
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
N Engl J Med. 2008 Jun 12;358(24):2585-93
pubmed: 18463370
Nat Genet. 2013 Mar;45(3):279-84
pubmed: 23334666
J Alzheimers Dis. 2011;27(1):197-210
pubmed: 21799244
J Clin Oncol. 2015 Sep 20;33(27):3008-17
pubmed: 26304901
Hum Mol Genet. 2010 Sep 1;19(17):3343-53
pubmed: 20566709
PLoS Genet. 2011 Mar;7(3):e1002026
pubmed: 21436895
Nat Rev Drug Discov. 2013 Nov;12(11):829-46
pubmed: 24113830
Front Immunol. 2018 Jul 12;9:1605
pubmed: 30050539
Mitochondrion. 2018 Mar;39:43-50
pubmed: 28851673
Nature. 2011 Jan 13;469(7329):216-20
pubmed: 21124317
Eur J Hum Genet. 2005 Aug;13(8):965-9
pubmed: 15886711
Bioinformatics. 2010 Jan 1;26(1):139-40
pubmed: 19910308
Front Immunol. 2017 Nov 03;8:1473
pubmed: 29163537
Mol Ecol Resour. 2018 Jul;18(4):789-797
pubmed: 29673087
Neurobiol Aging. 2010 Aug;31(8):1355-63
pubmed: 20538375
Nat Genet. 2009 Jun;41(6):718-23
pubmed: 19412175
Mitochondrion. 2011 Nov;11(6):855-61
pubmed: 21586348
Ann Neurol. 2014 Feb;75(2):186-95
pubmed: 24523223
Nucleic Acids Res. 2016 Jul 8;44(W1):W58-63
pubmed: 27084951
Cancer Res. 2012 Feb 1;72(3):686-95
pubmed: 22174369
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
PLoS One. 2015 Jun 08;10(6):e0129802
pubmed: 26053068
Nature. 2009 May 28;459(7246):528-33
pubmed: 19404256
BMC Cancer. 2010 Apr 19;10:149
pubmed: 20398431
Eur J Hum Genet. 2005 Jun;13(6):748-52
pubmed: 15827561
J Clin Invest. 2007 Sep;117(9):2702-12
pubmed: 17710228
Lancet. 2007 Jun 23;369(9579):2106-20
pubmed: 17586306
Cell. 2015 Sep 24;163(1):33-8
pubmed: 26406369
Nat Commun. 2017 Sep 18;8(1):569
pubmed: 28924153
Front Oncol. 2013 Jun 26;3:167
pubmed: 23805414
Am J Hum Genet. 2007 Sep;81(3):559-75
pubmed: 17701901
Oncotarget. 2017 Jan 24;8(4):7175-7180
pubmed: 27764780
J Clin Oncol. 1993 Aug;11(8):1466-77
pubmed: 8336186
Hum Genet. 2014 Jul;133(7):861-8
pubmed: 24488180
N Engl J Med. 2010 Jun 10;362(23):2202-11
pubmed: 20558371
Cancer. 2003 Nov 15;98(10):2274-81
pubmed: 14601099